



OPEN ACCESS

EDITED BY

Xiaoyun Mao,
The First Affiliated Hospital of China Medical
University, China

REVIEWED BY

Marina Guvakova,
University of Pennsylvania, United States
Somchanin Pipatpajong,
Chulalongkorn University, Thailand

*CORRESPONDENCE

Henrique Lima Couto
✉ enriquecouthotmail.com

RECEIVED 26 April 2025

ACCEPTED 29 September 2025

PUBLISHED 24 October 2025

CORRECTED 18 November 2025

CITATION

Couto HL, Valadares CN, Soares AN, Ricardo BFP, Toppa PH, Coelho BA, Pessoa EC, Resende V, Ferreira TCO, Mattar A, Amorim A, Clarke P, Freitas-Junior R, Silva Junior GA, Sharma N, Bartels HS, de Paula CAJ, Cunha Júnior GF, Oliveira DRP, Silvestre da Silva BT, Siqueira DR, Castilho MS, Antonini M, de Amorim HLE, de Oliveira JS, Pires BAM, Pires DM, Ferreira SG, Moraes TP, Oliveira LB, Soares PMC, de Oliveira VM, dos Santos AMR, Rahal RMS, Hassan AT, de Lucena CEM, Tosello G, Buttros DAB, Novita G, Saliba RGR, Carvalho BPSA, de Almeida Junior WJ, Ramos MDNM, Mendonça ACG and Reis FM (2025) Vacuum-assisted biopsy in the era of low-risk ductal carcinoma *in situ* active monitoring: real world data and implications. *Front. Oncol.* 15:1618476. doi: 10.3389/fonc.2025.1618476

COPYRIGHT

© 2025 Couto, Valadares, Soares, Ricardo, Toppa, Coelho, Pessoa, Resende, Ferreira, Mattar, Amorim, Clarke, Freitas-Junior, Silva Junior, Sharma, Bartels, de Paula, Cunha Júnior, Oliveira, Silvestre da Silva, Siqueira, Castilho, Antonini, de Amorim, de Oliveira, Pires, Pires, Ferreira, Moraes, Oliveira, Soares, de Oliveira, dos Santos, Rahal, Hassan, de Lucena, Tosello, Buttros, Novita, Saliba, Carvalho, de Almeida Junior, Ramos, Mendonça and Reis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Vacuum-assisted biopsy in the era of low-risk ductal carcinoma *in situ* active monitoring: real world data and implications

Henrique Lima Couto^{1,2*}, Carolina Nazareth Valadares^{3,4}, Aleida Nazareth Soares^{5,6}, Bernardo Ferreira de Paula Ricardo⁷, Paola Hartung Toppa⁶, Bertha Andrade Coelho^{8,9}, Eduardo Carvalho Pessoa^{10,11}, Vivian Resende¹², Tereza Cristina de Oliveira Ferreira¹, Andre Mattar¹³, Andressa Amorim¹³, Paula Clarke¹⁴, Rufo Freitas-Junior¹⁵, Gabriel de Almeida Silva Junior¹⁶, Nisha Sharma¹⁷, Henrique Silva Bartels¹⁴, Charles André Joseph de Paula¹⁸, Geraldo Felício Cunha Júnior¹⁸, Dênia Reis de Paula Oliveira¹⁹, Bruna Torres Silvestre da Silva¹, Daniela Rodrigues Siqueira¹, Marcus Simões Castilho¹⁹, Marcelo Antonini²⁰, Heverton Leal Ernesto de Amorim²¹, Jane Sanglard de Oliveira¹, Bruna Antunes de Miranda Pires¹, Douglas de Miranda Pires^{1,22}, Shirley das Graças Ferreira¹, Thais Paiva Moraes^{1,23}, Larissa Barbosa Oliveira¹, Paula Martins Cristina Soares¹, Vilmar Marques de Oliveira²⁴, Annamaria Massaud Rodrigues dos Santos^{16,22,25}, Rosemar Macedo Souza Rahal¹⁵, Augusto Tufi Hassan^{4,26}, Clécio Ênio Murta de Lucena¹², Giuliano Tosello²⁷, Daniel de Araújo Brito Buttros^{10,28}, Guilherme Novita²⁹, Romana Giordana Ribeiro Saliba¹, Bárbara Pace Silva Assis Carvalho³⁰, Waldeir José de Almeida Junior^{6,23}, Marcellus do Nascimento Moreira Ramos¹, Ana Carolina Guglielmelli Mendonça¹ and Fernando Marcos Reis¹²

¹Redimama-Redimasto Breast Unit, Belo Horizonte, Minas Gerais, Brazil, ²Brazilian Society of Mastology, Belo Horizonte, Minas Gerais, Brazil, ³Hospital Paulistano, São Paulo, São Paulo, Brazil, ⁴Brazilian Society of Mastology, Rio de Janeiro, Rio de Janeiro, Brazil, ⁵Faculdade de Saúde Santa Casa BH, Belo Horizonte, Minas Gerais, Brazil, ⁶Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ⁷Anatomia Laboratory, Belo Horizonte, Minas Gerais, Brazil, ⁸Mater Clínica, Montes Claros, Minas Gerais, Brazil, ⁹UNIFIPMOC University Center, Montes Claros, Minas Gerais, Brazil, ¹⁰São Paulo State University Júlio de Mesquita Filho, School of Medicine, Botucatu, Brazil, ¹¹Brazilian Society of Mastology, São Paulo, São Paulo, Brazil, ¹²Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ¹³Women Hospital, São Paulo, São Paulo, Brazil, ¹⁴Military Hospital of the Institute of Social Security of Military Servants of Minas Gerais, Belo Horizonte, Brazil, ¹⁵Federal University of Goiás, Goiânia, Goiás, Brazil, ¹⁶Orizonti Institute, Belo Horizonte, Minas Gerais, Brazil, ¹⁷Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹⁸CETUS Oncology, Belo Horizonte, Minas Gerais, Brazil, ¹⁹Radiocare, Belo Horizonte, Minas Gerais, Brazil, ²⁰Hospital of the State Public Servant of São Paulo, São Paulo, Brazil, ²¹UD Diagnóstica, João Pessoa, Paraíba, Brazil, ²²Santa Casa de Misericórdia Hospital, Belo Horizonte, Minas

Geraias, Brazil, ²³Mater Dei Hospital, Belo Horizonte, Minas Gerais, Brazil, ²⁴Faculty of Medical Sciences, Santa Casa of Sao Paulo, São Paulo, São Paulo, Brazil, ²⁵Institute of Social Security for State Employees of Minas Gerais (IPSEMG), Belo Horizonte, Minas Gerais, Brazil, ²⁶Oncoclínicas - CAM, Salvador, Bahia, Brazil, ²⁷Western Paulista Cancer Institute, Presidente Prudente, São Paulo, Brazil, ²⁸Faculty of Medicine of Claretiano University, Rio Claro, Brazil, ²⁹Oncoclínicas Group, São Paulo, São Paulo, Brazil, ³⁰Sonar Breast Unit, Belo Horizonte, Minas Gerais, Brazil

Background: The short-term oncological safe of active monitoring for ductal carcinoma *in situ* (DCIS) with low risk (LR-DCIS) of progression to invasive cancers (IC) has been demonstrated. This study evaluates vacuum assisted biopsy (VAB) as diagnostic test for LR-DCIS active monitoring (AM) in real-world clinical practice.

Methods: Database analysis of 116 cancers [both invasive breast cancers (IC) and ductal carcinoma *in situ* (DCIS)] diagnosed by VAB submitted to standard surgical treatment with complete histological data from VAB and surgery from 04/13/2017 to 11/28/2020. The VAB results matched the surgical pathology, considered the gold standard, and AM criteria. The pathological diagnoses were grouped into malignancies requiring guideline surgical treatment [DCIS with high risk (HR-DCIS) of progression to IC or IC] versus those eligible to alternative AM (LR-DCIS). HR-DCIS/IC were considered positive while LR-DCIS negative results. VAB sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were obtained.

Results: Mean age 55.6 [\pm 12.27]; mean IC size 7.14 [\pm 5.17]mm and 12.6 [\pm 11.63] mm for DCIS. Out of 116 malignancies diagnosed by VAB, 15 (12.9%) resulted LR-DCIS in the biopsy, 10 (8.6%) confirmed LR-DCIS in surgery, and 5 (4.3%) upgraded to HR-DCIS/IC in surgery. VAB showed 95.28% (89.3–98.5; 95% CI) sensitivity, 100% (69.2–100; 95% CI) specificity, PPV was 100% (96.4–100; 95% CI), and NPV 66.67% (38.4–88.2; 95% CI). VAB LR-DCIS AM was 6.9% (8/116) and underdiagnoses 2.6% (2 pT1a-bN0 hormone receptor positive and 1 HR-DCIS).

Conclusion: VAB LR-DCIS AM would lead to a moderate (6.9%) overall reduction of short-term breast cancer surgical overtreatment counterbalanced by a low rate (2.6%) of underdiagnosed HR-DCIS/IC potentially treatable by adjuvant hormone therapy.

Clinical Trial Registration: <https://plataformabrasil.saude.gov.br/visao/pesquisador/gerirPesquisa/gerirPesquisaAgrupador.jsf>, identifier 25761019.8.0000.5138.

KEYWORDS

breast cancer, vacuum assisted biopsy, enlarged vacuum assisted biopsy, vacuum assisted excision, DCIS, active monitoring

Highlights

- VAB is excellent in selecting breast cancer patients to guideline surgical treatment.
- VAB LR-DCIS active monitoring reduces breast cancer surgical overtreatment by 6.9%.
- IC overall undertreatment of VAB LR-DCIS active monitoring is 1.7%.

- Enlarged VAB is not superior to ordinary VAB in diagnosing LR-DCIS.

1 Introduction and objectives

The management of breast cancer has transitioned from generalized, radical treatments, such as radical mastectomy for all, to personalized and de-escalated strategies, incorporating targeted

therapies and breast-conserving surgery (1). Similarly, breast cancer diagnosis has evolved from diagnostic surgery and incisional biopsies to minimally invasive percutaneous procedures, including fine-needle aspiration (FNA), tru-cut core needle biopsies (CNB), and vacuum-assisted biopsy (VAB) (2).

Accurate histological diagnosis is essential for optimal therapeutic planning, aiming to achieve effective disease control while minimizing aesthetic and functional sequelae (3). Historically, cytological diagnosis via FNA was sufficient to initiate surgical treatment; however, in contemporary practice, precise histological and immunohistochemical diagnosis has become indispensable (2). In the context of personalized medicine, accurate percutaneous diagnosis is crucial for identifying breast malignancies that require immediate surgical, systemic, or radiotherapeutic interventions (4).

While distinguishing ductal carcinoma *in situ* (DCIS) from invasive carcinomas (IC) was previously a primary objective, the advent of de-escalated therapeutic approaches necessitates more nuanced diagnostic stratification (2). Specifically, differentiating DCIS with low risk (LR-DCIS) of progression to IC, with its favorable prognosis and potential for active monitoring (AM), from DCIS with high risk (HR-DCIS) of progression to IC is of paramount importance (5–17).

This study objective is to evaluate the diagnostic performance and clinical implications of VAB for LR-DCIS in real-world practice, within the framework of personalized medicine and emerging de-escalation strategies (5–19). The security for AM of LR-DCIS is dependent on the underdiagnosis risk of the method used. In this study, we compared results of VAB with the final surgical pathology and evaluated its impact in real world practice according to the eligibility criteria established in the COMET trial (18).

2 Methods

2.1 Patient eligibility and study design

The study was approved by the Ethics Committee of Santa Casa of Belo Horizonte under the number 25761019.8.0000.5138, and all methods were conducted in accordance with national guidelines. Written informed consent was obtained from all participants. The data set used and analyzed during the study is available upon reasonable request to the corresponding author.

A total of 1,061 vacuum-assisted biopsies (VAB) for suspicious breast lesions classified as BI-RADS 4, BI-RADS 5, or lesions with indeterminate malignant potential from prior CNB (B3 lesions per The Royal College of Pathologists) were performed at a dedicated breast diagnostic unit in Brazil between April 13, 2017, and November 28, 2020. Patients with benign histology on VAB, confirmed malignancy without primary surgical treatment, or unavailable final surgical pathology were excluded. The final study population included 116 women diagnosed with IC and DCIS with complete VAB and surgical pathology reports which were included in the analysis (Figure 1).

Baseline demographic data was recorded. Imaging data were collected, including baseline assessments, findings (mass \pm calcification), the image-guided approach used for VAB (ultrasound or stereotactic), and the maximum imaging tumor size (TI).

2.2 VAB procedure

A diagnostic VAB was performed. Following each procedure, a mammogram was obtained to confirm the position of the clip marker. VAB were classified as either ordinary VAB (OVAB) or enlarged VAB (EVAB). OVAB is defined by taking less than 12 core samples with a 7G needle or 18 core samples with a 10G needle, eventually the lesion is completely excised. EVAB was defined by complete lesion excision as confirmed by imaging or retrieval of more than 12 core samples with a 7G needle or 18 core samples with a 10G needle (20). The choice of biopsy device (EnCor Enspire™ Breast Biopsy System – BD or Mammotome Revolve™ Dual Vacuum Assisted Breast Biopsy System) and needle gauge was at discretion of the operating physician.


2.3 VAB/surgical pathological reports

Gross specimens were separated from clots, measured, weighed, and inked. All fragments were entirely included, and slices were sectioned at four-micron thickness. Cases typically ranged from one to five paraffin blocks. Histological evaluation included standard hematoxylin-eosin (HE) staining, with additional immunohistochemistry performed at the pathologist's discretion. Fluorescence *in situ* hybridization (FISH) and genetic analyses, such as Oncotype, were conducted if indicated.

All tissue samples underwent comprehensive histopathological evaluation. Pathological assessment included measurement of the maximum tumor size, determination of diagnosis (IC \pm DCIS), presence of DCIS with necrosis, multifocality (surgical specimen), biomarker status (ER, PR, HER2, Ki67), morphological tumor type, and nuclear and histological grades. The maximum pathological tumor size following VAB was defined as the largest tumor dimension observed on the slide containing the most extensive tumor involvement (21). Sentinel node biopsy (SNB) was performed according to standard clinical practice (22). The presence of residual invasive or *in situ* disease in the surgical specimen was documented. The pathological reports followed The College of American Pathologists Guidelines and World Health Organization Classification of Tumors of the Breast (23–31).

HR-DCIS was defined as any high-grade ductal carcinoma *in situ*, while LR-DCIS was defined as low- or intermediate-grade ductal carcinoma *in situ* with or without necrosis (7, 18).

For multicentric or bilateral breast cancers, only the tumor measurements and outcomes related to the lesion sampled by VAB were analyzed. One patient with two multicentric nodules underwent separate VAB procedures for each lesion; these were treated as distinct cases. These cases were automatically excluded for potential AM.



All cases underwent surgical excision following VAB. Postoperatively, radiography of the surgical specimen was performed to confirm the presence of the marker placed during VAB.

2.4 Diagnostic test statistical evaluation

An exploratory analysis was initially conducted to assess the normality of the data with continuous distribution. To this end, the Shapiro-Wilk test was used. For continuous variables, measures of central tendency (mean and median) and dispersion (standard deviation) were obtained. For categorical variables, frequency and percentage for each category were calculated.

OVAB and EVAB variables were compared to evaluate potential selection bias and disparities in the cohort that could influence the results. For continuous variables (OVAB vs. EVAB), comparisons were performed using the Mann-Whitney test, which is applied in pairwise comparisons of unpaired samples. Fisher's Exact Test was used for comparisons between frequencies obtained in each categorical variable. This test was chosen due to the characteristics of the analyzed sample and the presence of very low values, which made it impossible to apply the Chi-square test across all variables. Therefore, to ensure consistency in the analysis, Fisher's Exact Test was adopted for all frequency comparisons. In all analyses performed, the obtained differences were considered statistically significant when the p-value was less than or equal to 0.05 ($p \leq 0.05$).

To evaluate the diagnostic test, the pathological results of OVAB and EVAB were analyzed both separately and collectively (VAB), using surgical pathology as the gold standard for comparison. Pathological diagnoses were categorized into malignancies requiring guideline surgical treatment versus those eligible for potential AM. Lesions necessitating guideline surgical intervention were classified as positive and included IC and HR-DCIS. Lesions eligible for AM were classified as negative and included LR-DCIS.

To evaluate the association between VAB results and the surgical gold standard, 2x2 contingency tables were analyzed. VAB HR-DCIS/IC (positive) and VAB LR-DCIS (negative) were compared to surgical final pathology. Diagnostic performance metrics, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy, were calculated for each comparison with a confident interval (CI) of 95%. VAB LR-DCIS results were matched to COMET inclusion and exclusion criteria (18) (Table 1).

Statistical analyses were performed using Graphpad Prism[®] software (GraphPad Software, version 8.0, La Jolla California USA, www.graphpad.com) for Windows, the GraphPad QuickCalcs software for detecting potential outlier values, and Stata[®] (version 14.0, Stata Corporation, College Station, TX, USA).

Statistical analyses of the diagnostic test performance were conducted using Stata[®] (version 14.0, Stata Corporation, College Station, TX, USA) employing the *diagt* command to estimate sensitivity, specificity, PPV, NPV, and their corresponding 95% confidence intervals.

3 Results

3.1 Cohort

In the general study population, the mean age was 55.66 years (± 12.27). The mean final tumor size was 7.14 mm (± 5.17) for IC (T) and 12.61 mm (± 11.63) for DCIS. Among the cases, 56.03% underwent EVAB, while 43.97% underwent OVAB (Table 2).

Patients undergoing EVAB demonstrated statistically higher median values compared with the OVAB group for the following parameters: largest VAB tumor size, estrogen receptor (ER) expression, and progesterone receptor (PR) expression. In contrast, OVAB patients exhibited statistically higher medians compared with EVAB patients for the following parameters: largest image size, residual DCIS tumor size, and Ki67 index (Table 2).

TABLE 1 COMET inclusion/exclusion criteria (18).

COMET criteria	Inclusion	Exclusion
Age	≥40	<40
DCIS	Grade 1 or 2	Grade 3
HR	+	-
HER 2	-	+
Lesion type	Calcifications	mass
Symptoms	Absent	Present

DCIS, ductal carcinoma *in situ*; HR, hormone receptor; HER 2, Human Epidermal growth factor Receptor-type 2. Her 2-: 0-1/3+ in immunohistochemistry or 2/3+ in immunohistochemistry with fluorescence *in situ* hybridization (FISH) negative; HER 2+: 3/3+ in immunohistochemistry or 2/3+ in immunohistochemistry with fluorescence *in situ* hybridization (FISH) positive.

For categorical variables, the general study population demonstrated the following characteristics: 91.38% of procedures were performed by a single physician, 65.52% were ultrasound-guided, and 42.24% involved masses only. Unifocal lesions were present in 87.07% of cases, and 95.69% were not multicentric or bilateral. Intermediate nuclear grade was observed in 48.28% of cases. In the final pathology 67.24% were IC and 32.75% were DCIS. Among surgical interventions, 77.39% were lumpectomies (Table 3).

When comparing EVAB and OVAB groups, significant differences were identified in several variables. The majority of EVAB procedures were ultrasound-guided, whereas most OVAB procedures were stereotactically guided. Masses were more frequently sampled with EVAB, while calcifications predominated in OVAB cases. Pathological findings of IC + DCIS were more common in EVAB, whereas DCIS was predominant in OVAB. Also, in final pathology IC + DCIS were more common in EVAB, whereas DCIS was predominant in OVAB. Although lumpectomy was the most frequent surgery in both groups, EVAB cases had a statistically higher lumpectomy rate than OVAB (Table 3).

3.2 Diagnostic test performance

The comparison between VAB LR-DCIS and surgical gold standard pathology is shown in Table 4. VAB LR-DCIS upstaging rate was 33.33%.

The calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of VAB, OVAB and EVAB, compared with the surgical gold standard are shown in Tables 5 and 6.

The 15 VAB LR-DCIS cases matched surgical outcome and COMET criteria are outlined in Table 7.

There were 5 false-negative (FN) LR-DCIS cases identified across VAB. Of these, 3 cases (60%) occurred in EVAB, and 2 cases (40%) occurred in OVAB. Among the FN cases, 3 (60%) were upgraded to HR-DCIS, and 2 (40%) were upgraded to IC. The majority (80%) of FN cases were in patients over 40 years old, with 1 case (20%) in a patient under 40 years. Imaging findings included

grouped calcifications in 4 cases (80%) and a mass in 1 case (20%). All lesions were ≤25 mm in size. Surgical management included 4 lumpectomies (80%) and 1 mastectomy (20%), with sentinel node biopsy (SNB) performed in 2 cases (40%) and no axillary evaluation in 3 cases (60%) (Table 7).

Of the 3 patients upgraded to HR-DCIS, 1 had ER/PR/HER2-negative status, 1 was under 40 years old, and 1 presented with a mass on imaging. Among the 2 cases upgraded to IC, one was an invasive ductal carcinoma (IDC) pT1b (6 mm, HG3, ER 100%, PR 5%, HER2-negative, Ki67 55%) pN0sn, and the other was pT1a (IDC, 2 mm, HG2, ER 100%, PR 100%, HER2-negative, Ki67 5%) N0 (Table 7).

There were 10 true-negative (TN) cases of LR-DCIS. Of these, 9 cases (90%) involved patients over 40 years of age, and 1 case (10%) involved a patient under 40. Imaging findings included calcifications in 7 cases (70%), masses in 2 cases (20%), and a mass associated with calcifications in 1 case (10%). Procedural distribution revealed that 6 cases (60%) were diagnosed using OVAB, and 4 cases (40%) were diagnosed using EVAB. Surgical management included 9 lumpectomies (90%) and 1 mastectomy (10%). SNB was performed in 1 case (10%), with no axillary procedure in the remaining 9 cases (90%). Complete resection of DCIS during biopsy was achieved in 5 cases (50%), comprising 3 OVAB cases and 2 EVAB cases.

When the whole cohort is compared with the COMET trial criteria, 7 cases (46.7%) would have been excluded: 2 cases (13.3%) due to age under 40, 4 cases (26.6%) due to mass findings on imaging, and 2 cases (13.3%) due to hormone receptor status (1 triple-negative and 1 HR+, HER2+). Of notice: 1 of these cases was a 31-year-old patient presenting with a mass (18) (Table 7).

VAB LR-DCIS AM, according to COMET, would represent 6.9% (8/116) of all VAB cancers with 2.6% (3/116) underdiagnosed cases: 2 pT1a-bN0 hormone receptor positive breast cancers and 1 HR-DCIS (Figure 2).

4 Discussion

Our series, as far as we know, is the first to evaluate the impact of EVAB on the accurate diagnosis of LR-DCIS for active monitoring. Although extended vacuum procedures, such as EVAB and VAE, reduce the upgrade rate of DCIS diagnosed with biopsy to invasive cancers in surgery when compared with CNB (30), EVAB did not reduce upgrade rate of LR-DCIS to HR-DCIS or IC in surgery compared with OVAB in our series. EVAB was more frequent in masses and therefore was mostly guided by US. It is well known that presence of a mass increases the risk of VAB DCIS upstaging to IC in surgery (32). The lack of statistical difference between OVAB and EVAB could be explained by some potential selection bias. On the other hand, the results strengthen the recommendation of mass as exclusion criteria for VAB LR-DCIS AM (18).

Our series demonstrated that, in real-world practice based on conventional eosin-hematoxylin pathology, the upstaging of VAB

TABLE 2 Descriptive and comparative analysis of continuous variables (VAB, EVAB and OVAB).

Continuous variables	Mean	± SD	Median	P25 - P75	Min - max	P value ^{MW}
Age (years)						0,0855
VAB (n=116)	55,66	± 12,27	56,00	46 - 65	20 - 91	
EVAB (n=65)	57,38	± 12,78	58,00	48 - 66	31 - 91	
OVAB (n=51)	53,47	± 11,35	51,00	45 - 63	20 - 76	0,0175*
Largest image size (mm) (n=78)						
VAB (n=78)	11,67	± 10,59	9,00	6,95 - 13,25	4 - 88	
EVAB (n=59)	9,58	± 4,64	9,00	6 - 10	5 - 26	0,0451*
OVAB (n=19)	18,15	± 18,75	14,00	8 - 25	4 - 88	
Largest VAB T measurement (mm) (n=106)						
VAB (n=106)	5,29	± 2,89	5,00	4 - 6,63	1 - 25	0,2694
EVAB (n=61)	5,81	± 3,35	5,00	4 - 7	1,75 - 25	
OVAB (n=45)	4,58	± 1,95	4,00	3,13 - 6	1 - 9	
Residual IC T (n=113)						<0,0001*
VAB (n=113)	2,95	± 5,48	0,00	0 - 3	0 - 25	
EVAB (n=64)	3,27	± 5,61	0,00	0 - 4	0 - 25	
OVAB (n=49)	2,53	± 5,34	0,00	0 - 1	0 - 23	0,0001*
Residual DCIS T (n=110)						
VAB (n=110)	7,57	± 11,25	2,00	0 - 13,25	0 - 65	
EVAB (n=62)	3,58	± 6,72	0,00	0 - 3,25	0 - 30	<0,0001*
OVAB (n=48)	12,73	± 13,66	10,00	0 - 20,75	0 - 65	
ER (%) (n=114)						
VAB (n=114)	68,75	± 39,34	90,00	40 - 100	0 - 100	0,0001*
EVAB (n=65)	79,82	± 33,11	100,00	70 - 100	0 - 100	
OVAB (n=49)	54,08	± 42,39	70,00	0 - 95	0 - 100	
PR (%) (n=114)						<0,0001*
VAB (n=114)	50,44	± 41,48	60,00	0,75 - 90	0 - 100	
EVAB (n=65)	63,15	± 40,50	80,00	10 - 100	0 - 100	
OVAB (n=49)	33,57	± 36,80	10,00	0 - 80	0 - 100	0,0109*
KI67 (%) (n=112)						
VAB (n=112)	22,07	± 19,11	20,00	10 - 30	2 - 90	
EVAB (n=65)	18,94	± 18,04	10,00	5 - 25	2 - 80	0,1702
OVAB (n=47)	26,40	± 19,89	20,00	10 - 30	2 - 90	
Final IC T (mm) (n=76)						
VAB (n=76)	7,14	± 5,17	6,00	4 - 9,75	0,8 - 25	0,1673
EVAB (n=51)	7,45	± 4,68	6,00	4 - 9	2 - 25	
OVAB (n=25)	6,51	± 6,10	5,00	1 - 10	0,8 - 23	
Final DCIS T (mm) (n=37)						0,1673
VAB (n=37)	12,61	± 11,63	8,00	5 - 19	2 - 65	

(Continued)

TABLE 2 Continued

Continuous variables	Mean	± SD	Median	P25 - P75	Min - max	P value ^{MW}
EVAB (n=12)	8,29	± 5,22	7,00	4,25 - 11	2,5 - 20	
OVAB (n=25)	14,68	± 13,29	13,00	5 - 20,50	2 - 65	

VAB, vacuum assisted biopsy; OVAB, ordinary vacuum assisted biopsy; EVAB, enlarged vacuum assisted biopsy; SD, standard deviation; P25, 25th percentile; P75, 75th percentile; Min, minimum value; Max, maximum value. MW, Mann-Whitney test; * statistical significance ($p \leq 0.05$).
 Bold values: Statistically significant.

TABLE 3 Descriptive and comparative analysis of categorical variables (VAB, EVAB, and OVAB).

Categorical variables	VAB (n=116)		EVAB (n=65)		OVAB (n=51)		P value ^F
	N	%	N	%	N	%	
Performing physician							
Dr. 1	106	91,38	59	90,77	47	92,16	0,932
Dr. 2	4	3,45	2	3,08	2	3,92	
Dr. 3	4	3,45	3	4,62	1	1,96	
Dr. 4	2	1,72	1	1,54	1	1,96	
US or MMG							
US	76	65,52	56	86,15	20	39,22	<0,0001*
MMG	40	34,48	9	13,85	31	60,78	
Mass/calcifications							
Mass	49	42,24	40	61,54	9	17,65	<0,0001*
Mass + Calcs	31	26,72	19	29,23	12	23,53	
Calcs	36	31,03	6	9,23	30	58,82	
Multifocal							
No	101	87,07	58	89,23	43	84,31	0,579
Yes	15	12,93	7	10,77	8	15,69	
Multicentric/bilateral							
No	111	95,69	64	98,46	47	92,16	0,167
Yes	5	4,31	1	1,54	4	7,84	
VAB pathology							
Invasive Cancer (IC)	26	22,41	22	33,85	4	7,84	<0,0001*
DCIS	43	37,07	15	23,08	28	54,90	
IC + DCIS	36	31,03	26	40,00	10	19,61	
DCIS + microinvasion	11	9,48	2	3,08	9	17,65	
DCIS with comedonecrosis							
No	59	50,86	45	69,23	14	27,45	<0,0001*
Yes	56	48,28	19	29,23	37	72,55	
DCIS absent	1	0,86	1	1,54	0	0,00	
Histological grade (n=68)							
Low	18	26,47	16	30,77	2	12,50	0,204
Intermediate	34	50,00	26	50,00	8	50,00	

(Continued)

TABLE 3 Continued

Categorical variables	VAB (n=116)		EVAB (n=65)		OVAB (n=51)		P value ^F
	N	%	N	%	N	%	
Histological grade (n=68)							
High	16	23,53	10	19,23	6	37,50	
Nuclear grade							
Low	12	10,34	9	13,85	3	5,88	0,031
Intermediate	56	48,28	36	55,38	20	39,22	
High	48	41,38	20	30,77	28	54,90	
Final pathology							
Invasive cancer	18	15,52	15	23,08	3	5,88	<0,0001*
Invasive cancer + DCIS	52	44,83	37	56,92	15	29,41	
DCIS	38	32,75	12	18,46	26	50,98	
CDIS + microinvasion	8	6,90	1	1,54	7	13,73	
Axillary nodes pathology (n=84)							
pN0	75	89,29	45	88,24	30	90,91	1,000
1 metastatic node	5	5,95	3	5,88	2	6,06	
2 metastatic nodes	3	3,57	2	3,92	1	3,03	
3 metastatic nodes	1	1,19	1	1,96	0	0,00	
HER-2 (n=113)							
Negative	84	74,34	54	83,08	30	62,50	0,023*
Indeterminate 2+	2	1,77	1	1,54	1	2,08	
Positive	27	23,89	10	15,38	17	35,42	
Immunohistochemical like subtypes (n=78)							
Luminal A	32	41,03	25	47,17	7	28,00	0,040*
Luminal B	25	32,05	18	33,96	7	28,00	
Luminal Her	7	8,97	5	9,43	2	8,00	
Pure Her	6	7,69	1	1,89	5	20,00	
Triple negative	8	10,26	4	7,55	4	16,00	
Hormonal receptors positive (>10) Her negative (n=78)							
No	21	26,92	10	18,87	11	44,00	0,029*
Yes	57	73,08	43	81,13	14	56,00	
Type of surgery (n=115)							
Lumpectomy	89	77,39	55	84,62	34	68,00	0,044*
Mastectomy	26	22,61	10	15,38	16	32,00	

VAB, vacuum assisted biopsy; OVAB, ordinary vacuum assisted biopsy; EVAB, enlarged vacuum assisted biopsy; n, absolute frequency; %, percentage; F, Fisher's Exact Test; * statistical significance (p ≤ 0.05). MMG, mammography.

Bold values: Statistically significant.

for HR-DCIS/IC was as high as 33.33%. Moreover, there was no significant improvement in upstaging with the extension of the vacuum procedure: EVAB (42.85%) versus OVAB (25%). Demographic, epidemiological, clinical, imaging and immunohistochemistry selection criteria are critical for improving

VAB's diagnostic accuracy and reducing false negative rate (FNR). In our study, the NPV of VAB for HR-DCIS/IC was 66.7%, a value directly influenced by the high prevalence of HR-DCIS/IC in the sample. Our upstaging rate was higher than reported in previous studies (6, 8, 10, 12), although those studies did not specifically

TABLE 4 VAB LR-DCIS comparison to surgical pathology.

VAB IC/DCIS	VAB LR-DCIS	Surgery LR-DCIS	Overall upstaging	HR-DCIS upstaging	IC upstaging
116(100%)	15(12.9%)	10(8.6%)	5(4.3%)	3(2.6%)	2(1.7%)

VAB, Vacuum assisted biopsy.

TABLE 5 Contingency table comparing results from VAB, OVAB, EVAB vs. surgery (Gold Standard).

Diagnostic Test		Final diagnosis after VAB and surgery		
		HR-DCIS/IC	LR-CDIS	Total
VAB	HR-DCIS/IC	101	0	101
	LR-DCIS	5	10	15
	Total	106	10	116
		Final diagnosis after ordinary VAB and surgery		
		HR-DCIS/IC	LR-DCIS	Total
OVAB	HR-DCIS/IC	43	0	43
	LR-CDIS	2	6	8
	Total	45	6	51
		Final diagnosis after EVAB and surgery		
		HR-DCIS/IC	LR-DCIS	Total
EVAB	HR-DCIS/IC	58	0	58
	LR-CDIS	3	4	7
	Total	61	4	65

VAB, vacuum assisted biopsy; OVAB, ordinary vacuum assisted biopsy; EVAB, enlarged vacuum assisted biopsy. Bold values: Statistically significant.

TABLE 6 VAB, OVAB, EVAB results.

	VAB (IC 95%)	OVAB (IC 95%)	EVAB (IC 95%)
Sensitivity	95.3% (89.3–98.5)	95.6% (84.9–99.5)	95.1% (86.3–99.0)
Specificity	100% (69.2–100)	100% (54.1–100)	100% (39.8–100)
PPV	100% (96.4–100)	100% (91.8–100)	100% (93.8–100)
NPV	66.7% (38.4–88.2)	75.0% (34.9–96.8)	57.1% (18.4–90.1)
Accuracy	95.7% (90.2–98.6)	96.1% (86.5–99.5)	95.4% (87.1–99.0)

VAB, vacuum-assisted biopsy; OVAB, ordinary VAB; EVAB, enlarged VAB; PPV, positive predictive value; NPV, negative predictive value; IC95%, 95% confidence interval.

evaluate NPV. Although VAB demonstrated excellent sensitivity and specificity, the probability that a negative result truly indicates the absence of HR-DCIS/IC remains limited. Furthermore, we highlight that in high-prevalence populations, a negative VAB result should be interpreted with caution and always considered in conjunction with rigorous active monitoring strategies.

Several trials have evaluated AM for LR-DCIS, each employing distinct inclusion and exclusion criteria (6–10, 12, 16, 18). Regarding diagnostic procedures, while VAB is included as an acceptable diagnostic modality in COMET (7, 18), LORIS (6, 8),

and LORD (16) trials, none distinguish between OVAB, EVAB, or vacuum-assisted excision (VAE). The COMET trial allows inclusion of LR-DCIS diagnosed via CNB or VAB without restrictions on the number of samples (7, 18). LORIS mandates at least a 12G needle for VAB, again with no restrictions on the number of samples (6, 8). LORD is unique in requiring a minimum of 6 samples with an 8-9G needle or 12 samples with a 10-11G needle (16).

Retrospectively VAB LR-DCIS upstaging risk to HR-DCIS/IC in surgery varies from 5% to 12% according to inclusion criteria, LORD, LORIS, COMET (6, 8, 10). These trials apply different inclusion criteria beyond just conventional HE pathology. In our series, VAB LR-DCIS upstaging to HR-DCIS/IC was high (33.33%) probably because it considered just conventional, HE pathology. So, it is very important to associate clinical, imaging and immunohistochemistry data to refine the selection criteria of VAB LR-DCIS AM.

Despite the retrospective data, COMET prospective published data demonstrated that two years incidence of IC was 8.7% in the LR-DCIS guideline-concordant care (surgery with or without radiation therapy) versus 3.1% in the AM group, leading the inference that IC upstaging would be approximately 8.7% in the AM group (18). In our series, applying COMET criteria, VAB LR-

TABLE 7 VAB LR-DCIS cases matched surgical outcome and COMET criteria.

VAB FN LR-DCIS pathology	Age (years)	Image finding	VAB	Surgery	Surgical pathology	Staging (21)	COMET criteria (18)
1- DCIS (NG2)	58	Calcifications	OVAB	Lumpectomy	DCIS (NG3; HR-; HER 2-)	pTis(13mm)	Inclusion
2- DCIS (NG2)	38	Calcifications	EVAB	Mastectomy + SNB	DCIS (NG3; HR+; HER 2-)	pTis(20mm) pN0	Exclusion
3- DCIS (NG2)	59	Calcifications	EVAB	Lumpectomy + SNB	IDC (HG3; HR+; HER 2-; Ki 67 55%)	pT1b(6mm) pN0sn	Inclusion
4- DCIS (NG1)	57	Mass	EVAB	Lumpectomy	DCIS (NG3; HR+; HER 2-)	pTis(25mm)	Exclusion
5- DCIS (NG2)	66	Calcifications	OVAB	Lumpectomy	IDC (HG2; HR+; HER 2-; Ki 67 5%)	pT1(2mm) N0.	Inclusion
VAB TN LR-DCIS pathology							
1- DCIS (NG1)	46	Calcifications	EVAB	Lumpectomy	DCIS (NG1; HR+; HER 2-)	pTis(2,5mm)	Inclusion
2- DCIS (NG2; HR+; HER 2-)	31	Mass	EVAB	Lumpectomy	No residual tumor	pTis(4mm)	Exclusion
3- DCIS (NG1; HR+; HER 2-)	70	Calcifications	OVAB	Lumpectomy	No residual tumor	pTis(3mm)	Inclusion
4- DCIS (NG2; HR+; HER 2-)	53	Mass	EVAB	Lumpectomy	No residual tumor	pTis(4mm)	Exclusion
5- DCIS (NG2)	70	Calcifications	OVAB	Lumpectomy	DCIS (NG2; HR+; HER2-)	pTis(5mm)	Inclusion
6- DCIS (NG2; HR-; HER 2+)	62	Calcifications	OVAB	Lumpectomy	DCIS (NG2; HR-; HER 2+)	pTis(2mm)	Exclusion
7- DCIS (NG2; HR-; HER2-)	60	Calcifications	OVAB	Lumpectomy	No residual tumor	pTis(4mm)	Exclusion
8- DCSI (NG1; HR+; HER-)	45	Calcifications	OVAB	Lumpectomy	No residual tumor	pTis(2mm)	Inclusion
9- DCIS (NG2)	46	Calcifications	OVAB	Mastectomy + BLS	DCIS (NG2; HR+; HER 2-)	pTis(14mm) pN0sn	Inclusion
10- DCIS (NG2)	62	Mass associated to calcifications	EVAB	Lumpectomy	DCIS (NG2; HR+; HER 2-)	pTis(8mm)	Exclusion

FN, false negative; TN, true negative; VAB, vacuum assisted biopsy; OVAB, ordinary vacuum assisted biopsy; EVAB, enlarged vacuum assisted biopsy; DCIS: ductal carcinoma *in situ*; IDC, invasive ductal carcinoma; HR-DCIS, ductal carcinoma *in situ* with high risk of progression to invasive cancer; LR-DCIS, ductal carcinoma *in situ* with low risk of progression to invasive cancer; HR, hormone receptor; NG, nuclear grade; HG, histological grade; SNB, sentinel node biopsy.




FIGURE 2 VAB real world data for LR-DCIS active monitoring. VAB, Vacuum assisted biopsy; HR-DCIS, Ductal carcinoma *in situ* with high risk of progression; LR-DCIS, Ductal carcinoma *in situ* with low risk of progression; AM, Active monitoring.

DCIS upstaging rate to IC was 28.6, higher than COMET. The limited number of the sample could explain the difference.

Of the 15 cases of LR-DCIS identified on VAB, 5 were completely excised by the biopsy. Complete pathological excision of LR-DCIS during biopsy eliminates the possibility of an upgrade during surgery and ensures the safety of AM. In this context,

vacuum assisted excision (VAE) may enhance the oncological safety of active surveillance by reducing the underestimation inherent in percutaneous needle diagnosis and represents an approach warranting consideration in future trials (33).

Based on COMET inclusion criteria (18), 2 (40%) upgraded false-negative (FN) cases from our series would be excluded, leaving

only 3 (60%). Of these, one was classified as pT1a (IDC, 2 mm, G2, ER 100%, PR 100%, HER2-negative, Ki-67 5%), one as pT1b (IDC, 6 mm, G3, ER 100%, PR 5%, HER2-negative, Ki-67 55%) pN0sn and one as HR-DCIS. Small, luminal stage I cancers (pT1a-bpN0) were the typical upgraded invasive malignancies observed in prior series (6, 8) and COMET trial (18). In COMET 94.7% of invasive cancers that were diagnosed in 2 years of AM were ER positive and 52.6% <1.1cm. For these patients, sentinel lymph node biopsy (SNB) can be safely omitted (34–36), and hormone therapy or radiation therapy, alone or combined, may suffice for disease control. In accordance, our series demonstrates the reproducibility of COMET in real world practice.

The upstaging of VAB LR-DCIS in our series was 33.33%, higher than reported in other studies (6, 8, 10, 12). Literature indicates significant interobserver variation in the classification of LR-DCIS (37–41). Besides, there is always the chance of misdiagnoses in VAB. Our results highlight the potential need for a double reading of pathology reports prior to initiating LR-DCIS AM. The COMET trial required concordance between two clinical pathologists to mitigate interobserver variation (7, 18). Another potential strategy to address interobserver variation and reduce FNR is the use of artificial intelligence (AI), which is currently under evaluation and development (42).

Demographic, epidemiological, clinical, imaging and immunohistochemistry selection criteria are critical for improving VAB's diagnostic accuracy and reducing FNR. When COMET trial criteria were applied to our series, 7 patients (6.0%) would be excluded, leaving 8 (6.9%) eligible for AM, of whom 3 (2.6%) would represent FN cases of LR-DCIS. Thus, in real-world practice from April 13, 2017, to November 28, 2020, AM for VAB LR-DCIS applying COMET criteria would reduce approximately 8 (6.9%) cases of breast cancer overtreatment, counterbalanced by 3 (2.6%) potentially undertreated HR-DCIS/IC. Consequently, 7 patients (6.0%) would have avoided lumpectomy, 1 (0.8%) mastectomy and 2 (1.7%) sentinel node biopsy.

Our study has some limitations. In our study, the NPV represents the probability that a lesion diagnosed as LR-DCIS by VAB truly does not correspond to HR-DCIS or IC at final surgery. It is important to note that the 95% confidence intervals for the NPV were wide (e.g., 18.4–90.1% for EVAB), reflecting both the high prevalence of HR-DCIS/IC and the relatively small number of truly negative cases. This finding underscores the need for cautious interpretation of negative VAB results in the present study, particularly in the context of AM strategies.

Of the 133 VAB cancers found, 17 were excluded due to lack of surgical pathology report. Although it could lead to selection bias, it is quite improbable. As the whole cohort, these were cases of IC/DCIS and the prevalence of VAB LR-DCIS was 12.9%. It was expected to be around 2 more cases of VAB LR-DCIS. The upstage rate would range from 29.4% (2 TN) to 41.2% (2 FN), still high and comparable to the 33.33% found. COMET allowed inclusion of patients diagnosed with LR-DCIS by CNB, VAB and diagnostic open surgery. Our series is restricted to VAB. Although the limited size of the sample, the findings are still valuable and reflect

real world practice. The analysis was retrospective and there were differences between OVAB and EVAB cohort that could lead to potential selection bias. A prospective trial to evaluate OVAB versus EVAB or even VAE for LR-DCIS diagnosis would be recommended.

5 Conclusion

VAB LR-DCIS active monitoring based on COMET criteria would lead to a moderate overall reduction (6.9%) of short-term breast cancer surgical overtreatment counterbalanced by a low rate (2.6%) of underdiagnosed HR-DCIS/IC potentially treatable by adjuvant hormone therapy in real world clinical practice. The diagnosis of LR-DCIS using VAB, based on conventional pathology, demonstrates a low negative predictive value (NPV) for high-risk DCIS (HR-DCIS) or invasive carcinoma (IC) in real-world clinical practice. EVAB is not superior to ordinary VAB in reducing the underdiagnosis of HR-DCIS/IC.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The study was approved by Ethics Committee of Santa Casa of Belo Horizonte. The study was conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

HC: Methodology, Formal analysis, Writing – review & editing, Software, Supervision, Investigation, Writing – original draft, Visualization, Conceptualization, Validation, Funding acquisition, Data curation, Project administration, Resources. CV: Data curation, Investigation, Writing – review & editing. AS: Formal analysis, Writing – review & editing. BR: Investigation, Writing – review & editing, Data curation. PT: Investigation, Writing – review & editing, Data curation. BC: Writing – review & editing, Investigation. EP: Investigation, Writing – review & editing. VR: Writing – review & editing, Investigation. TF: Investigation, Writing – review & editing. AM: Writing – review & editing. AA: Investigation, Writing – review & editing. PC: Writing – review & editing, Investigation. RF: Investigation, Writing – review & editing. GS: Data curation, Writing – review & editing. NS: Writing – review & editing, Conceptualization, Investigation. HB: Writing – review & editing,

Data curation. CP: Writing – review & editing. GC: Writing – review & editing. DO: Data curation, Writing – review & editing. BS: Formal analysis, Writing – review & editing. DS: Data curation, Writing – review & editing. MC: Writing – review & editing. MA: Writing – review & editing. Investigation. HA: Investigation, Writing – review & editing. JO: Writing – review & editing, Data curation. BP: Data curation, Writing – review & editing. DP: Writing – review & editing, Investigation. SF: Data curation, Writing – review & editing. TM: Data curation, Writing – review & editing. LO: Writing – review & editing, Data curation. PS: Writing – review & editing, Data curation. VO: Writing – review & editing, Investigation. AR: Data curation, Writing – review & editing. RR: Data curation, Writing – review & editing. AH: Data curation, Writing – review & editing. CL: Writing – review & editing. GT: Writing – review & editing, Data curation. DB: Writing – review & editing, Investigation. GN: Data curation, Writing – review & editing. RS: Investigation, Writing – review & editing. BPSAC: Writing – review & editing, Data curation. WA: Writing – review & editing, Data curation. MR: Writing – review & editing, Data curation. ACGM: Data curation, Writing – review & editing. FR: Investigation, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Acknowledgments

The authors would like to thank all the patients that consent to this work.

References

- Heil J, Pfof A. Patients should be the tipping point of individualizing breast cancer surgery: Commentary on 'Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. *Ann Oncol.* (2020) 31:1264. doi: 10.1016/j.annonc.2020.05.021
- Bennett IC, Saboo A. The evolving role of vacuum assisted biopsy of the breast: A progression from fine-needle aspiration biopsy. *World J Surg.* (2019) 43:1054–61. doi: 10.1007/s00268-018-04892-x
- Palpable and nonpalpable breast lesions consensus guideline on image-guided percutaneous biopsy of palpable and nonpalpable breast lesions. *Am Soc Breast Surgeons.* (2017). Available online at: <https://www.breastsurgeons.org/docs/statements/asbrs-ccs-image-guided-biopsy.pdf> (Accessed October 07, 2025).
- Andrade AV, Lucena CÊM, Santos DCD, Pessoa EC, Mansani FP, Andrade FEM, et al. Accurate diagnosis of breast lesions. *Rev Bras Ginecol Obstet.* (2023) 45:215–20. doi: 10.1055/s-0043-1769468
- Pinder SE, Thompson AM, Wesslering J. Low-risk DCIS. What is it? Observe or excise? *Virchows Arch.* (2022) 480(1):21–32. doi: 10.1007/s00428-021-03173-8
- Grimm LJ, Ryser MD, Partridge AH, Thompson AM, Thomas JS, Wesseling J, et al. Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials. *Ann Surg Oncol.* (2017) 24:3534–40. doi: 10.1245/s10434-017-6018-9
- Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma *in situ* (DCIS). *BMJ Open.* (2019) 9:e026797. doi: 10.1136/bmjopen-2018-026797
- Oseni TO, Smith BL, Lehman CD, Vijapura CA, Pinnamaneni N, Bahl M. Do eligibility criteria for ductal carcinoma *in situ* (DCIS) active surveillance trials identify patients at low risk for upgrade to invasive carcinoma? *Ann Surg Oncol.* (2020) 27:4459–65. doi: 10.1245/s10434-020-08576-6
- Angarita FA, Brumer R, Castelo M, Esnaola NF, Edge SB, Takabe K. De-escalating the management of *in situ* and invasive breast cancer. *Cancers (Basel).* (2022) 14:4545. doi: 10.3390/cancers14194545
- Iwamoto N, Nara M, Horiguchi SI, Aruga T. Surgical upstaging rates in patients meeting the eligibility for active surveillance trials. *Jpn J Clin Oncol.* (2021) 51:1219–24. doi: 10.1093/jjco/hyab082
- Davey MG, Lowery AJ, Kerin MJ. Oncological safety of active surveillance for low-risk ductal carcinoma *in situ* - a systematic review and meta-analysis. *Ir J Med Sci.* (2023) 192:1595–600. doi: 10.1007/s11845-022-03157-w
- Soumian S, Verghese ET, Booth M, Sharma N, Chaudhri S, Bradley S, et al. Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed Low Risk DCIS Trial (LORIS). *Eur J Surg Oncol.* (2013) 39:1337–40. doi: 10.1016/j.ejso.2013.09.028
- Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma *in situ*. *JAMA Oncol.* (2015) 1:888–96. doi: 10.1001/jamaoncol.2015.2510
- Co M, Cheng KCK, Yeung YH, Lau KC, Qian Z, Wong CM, et al. Clinical outcomes of conservative treatment for low-risk ductal carcinoma *in situ*: A systematic review and pooled analysis. *Clin Oncol (R Coll Radiol).* (2023) 35(4):255–61. doi: 10.1016/j.clon.2023.01.019

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Correction note

This article has been corrected with minor changes. These changes do not impact the scientific content of the article.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

15. Podoll MB, Reisenbichler ES, Roland L, Bruner A, Mizuguchi S, Sanders MAG. Feasibility of the less is more approach in treating low-risk ductal carcinoma *in situ* diagnosed on core needle biopsy: ten-year review of ductal carcinoma *in situ* upgraded to invasion at surgery. *Arch Pathol Lab Med.* (2018) 142:1120–6. doi: 10.5858/arpa.2017-0268-OA
16. Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma *in situ* - The LORD study. *Eur J Cancer.* (2015) 51(12):1497–510. doi: 10.1016/j.ejca.2015.05.008
17. van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, et al. Ductal carcinoma *in situ*: to treat or not to treat, that is the question. *Br J Cancer.* (2019) 121(4):285–92. doi: 10.1038/s41416-019-0478-6
18. Hwang ES, Hyslop T, Lynch T, Ryser MD, Weiss A, Wolf A, et al. Active monitoring with or without endocrine therapy for low-risk ductal carcinoma *in situ*: the COMET randomized clinical trial. *JAMA.* (2025) 333(11):972–80. doi: 10.1001/jama.2024.26698
19. Partridge AH, Hyslop T, Rosenberg SM, Bennett AV, Drier S, Jonsson M, et al. Patient-reported outcomes for low-risk ductal carcinoma *in situ*: A secondary analysis of the COMET randomized clinical trial. *AMA Oncol.* (2025) 11(3):300–9. doi: 10.1001/jamaoncol.2024.6556
20. Valadares CN, Couto HL, Soares AN, Toppa PH, Ricardo BP, McIntosh SA, et al. Potential role of vacuum-assisted procedures in resecting breast cancers and highlighting selection criteria to support future trials. *Front Oncol.* (2023) 13:1239574. doi: 10.3389/fonc.2023.1239574
21. Hortobagyi GN, Connolly JL, D'Orsi CJ, Edge SB, Mittendorf EA, Hugo HS, et al. *AJCC cancer staging Manual, Breast*, Cham, Switzerland: Springer International Publishing Eighth Edition (2017). doi: 10.1007/978-3-319-40618-3_48.
22. Brazilian's guideline for breast cancer diagnoses and treatment. Available online at: http://conitec.gov.br/images/Relatorios/2018/Recomendacao/Relatorio_DDT_CarcinomaDeMama_2018.pdf (Accessed October 07, 2025).
23. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update. *Arch Pathol Lab Med.* (2018) 142:1364–82. doi: 10.5858/arpa.2018-0902-SA
24. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. *J Clin Oncol.* (2020) 38:1346–66. doi: 10.1200/JCO.19.02309
25. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch Pathol Lab Med.* (2010) 134:e48–72. doi: 10.5858/134.7.e48
26. College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. Available online at: https://documents.cap.org/documents/New-Cancer-Protocols-June-2025/Breast.Bmk_1.6.1.0.-REL_CAPCP.pd (Accessed October 07, 2025).
27. College of American Pathologists. Protocol for the Examination of Biopsy Specimens from Patients with Invasive Carcinoma of the Breast. Available online at: https://documents.cap.org/documents/Breast.Invasive.Bx_1.2.0.0.REL_CAPCP.pdf (Accessed October 07, 2025).
28. College of American Pathologists. Protocol for the Examination of Resection Specimens from Patients with Invasive Carcinoma of the Breast. Available online at: <https://documents.cap.org/protocols/cp-breast-invasive-resection-20-4400.pdf> (Accessed October 07, 2025).
29. College of American Pathologists. Protocol for the Examination of Resection Specimens from Patients with Ductal Carcinoma *In Situ* (DCIS) of the Breast. Available online at: https://documents.cap.org/protocols/Breast.DCIS_4.4.0.0.REL_CAPCP.pdf (Accessed October 07, 2025).
30. College of American Pathologists Protocol for the Examination of Biopsy Specimens from Patients with Ductal Carcinoma *In Situ* (DCIS) of the Breast. Available online at: https://documents.cap.org/protocols/Breast.DCIS.Bx_1.0.1.0.REL_CAPCP.pdf (Accessed October 07, 2025).
31. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ eds. *World Health Organization Classification of Tumours of the Breast* Vol. 4. Lyon, France: IARC (2012).
32. Park KW, Kim SW, Han H, Park M, Han BK, Ko EY, et al. Ductal carcinoma *in situ*: a risk prediction model for the underestimation of invasive breast cancer. *NPJ Breast Cancer.* (2022) 8:8. doi: 10.1038/s41523-021-00364-z
33. Nicosia L, Mariano L, Latronico A, Bozzini AC, Bellerba F, Gaeta A, et al. Exploring non-surgical alternatives for low to intermediate-grade *in situ* ductal carcinoma of the breast using vacuum-assisted excision: the VACIS protocol. *Front Med (Lausanne).* (2024) 14:67738. doi: 10.3389/fmed.2024.1467738
34. Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. *JAMA Oncol.* (2023) 9(11):1557–64. doi: 10.1001/jamaoncol.2023.3759
35. Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, et al. Axillary surgery in breast cancer - primary results of the INSEMA trial. *N Engl J Med.* (2024). doi: 10.1056/NEJMoa2412063
36. Park KU, Somerfield MR, Anne N, Brackstone M, Conlin AK, Couto HL, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. *J Clin Oncol.* (2025). doi: 10.1200/GDL.25.0410
37. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. *Hum Pathol.* (1992) 23:1095–7. doi: 10.1016/0046-8177(92)90026-Y
38. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. *Virchows Arch.* (1999) 434:3–10. doi: 10.1007/s004280050297
39. Elston CW, Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, et al. Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. *Eur J Cancer.* (2000) 36:1769–72. doi: 10.1016/S0959-8049(00)00181-7
40. O'Malley FP, Mohsin SK, Badve S, Bose S, Collins LC, Ennis M, et al. Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. *Mod Pathol.* (2006) 19:172–9. doi: 10.1038/modpathol.3800514
41. Jain RK, Mehta R, Dimitrov R, Larsson LG, Musto PM, Hodges KB, et al. Atypical ductal hyperplasia: interobserver and intraobserver variability. *Mod Pathol.* (2011) 24:917–23. doi: 10.1038/modpathol.2011.66
42. Alaeikhanehshir S, Voets MM, van Duijnhoven FH, Lips EH, Groen EJ, van Oirsouw MCJ, et al. Grand Challenge PRECISION Consortium Steering Group. Application of deep learning in mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials. *Cancer Imaging.* (2024) 24:48. doi: 10.1186/s40644-024-00691-x

Glossary

DCIS	ductal carcinoma in situ	PR	progesterone receptor
LR-DCIS	ductal carcinoma <i>in situ</i> with low risk of progression to invasive cancer	HER 2	Human epidermal growth factor receptor 2
IC	invasive cancer	Ki-67	protein Ki-67
VAB	vacuum assisted biopsy	SNB	sentinel node biopsy
HR-DCIS	ductal carcinoma <i>in situ</i> with high risk of progression to invasive cancer	COMET	Comparing an Operation to Monitoring, with or without Endocrine Therapy for low-risk ductal carcinoma <i>in-situ</i> (DCIS) of the breast
PPV	positive predictive value	T	pathological tumor size
NPV	negative predictive value	US	ultrasound
FNA	fine needle aspiration	MMG	mammography
CNB	core needle biopsy	FN	false negative
BI-RADS	Breast Image Reporting and Data System	TN	true negative
B3 lesions	lesions with indeterminate potential of malignance in core needle biopsy according to the Royal College of Pathologist	VAE	vacuum assisted excision
TI	maximum imaging tumor size	VAE Breast 01	Vacuum Assisted Excision, A single step approach to the diagnosis and treatment of lesions of indeterminate potential of malignance and early breast cancer
HE	hematoxylin-eosin	CMSH	Cavity margin sample shaving
FISH	Fluorescence <i>In Situ</i> Hybridization	AI	Artificial intelligence.
ER	estrogen receptor		